ACM
PVLA

ACT Capital Management’s Palvella Therapeutics PVLA Stock Holding History

ACT Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Buy
+22,500
New +$2.73M 2.25% 13

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ACT Capital Management's PVLA Position: Q2 2026 in Review

ACT Capital Management opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 22,500 shares worth $3.44M. The stake represents 2.25% of the portfolio and ranks #13 among its holdings.

196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • ACT Capital Management held 22,500 shares of Palvella Therapeutics worth $3.44M as of Q2 2026.
  • Palvella Therapeutics was a new ACT Capital Management position in Q2 2026.
  • Palvella Therapeutics made up 2.25% of ACT Capital Management's portfolio in Q2 2026, its #13 holding.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.